DexCom Inc (DXCM) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
DexCom Inc stock (DXCM) is currently trading at $66.84. DexCom Inc PE ratio is 31.98. DexCom Inc PS ratio (Price-to-Sales) is 5.59. Analyst consensus price target for DXCM is $87.44. WallStSmart rates DXCM as Moderate Buy.
- DXCM PE ratio analysis and historical PE chart
- DXCM PS ratio (Price-to-Sales) history and trend
- DXCM intrinsic value — DCF, Graham Number, EPV models
- DXCM stock price prediction 2025 2026 2027 2028 2029 2030
- DXCM fair value vs current price
- DXCM insider transactions and insider buying
- Is DXCM undervalued or overvalued?
- DexCom Inc financial analysis — revenue, earnings, cash flow
- DXCM Piotroski F-Score and Altman Z-Score
- DXCM analyst price target and Smart Rating
DexCom Inc
📊 No data available
Try selecting a different time range
DXCM Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · DexCom Inc (DXCM)
DXCM trades at a significant discount to its Graham intrinsic value of $97.81, offering a 30% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
DexCom Inc (DXCM) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in market cap, peg ratio, return on equity. Concerns around price/book. Overall metrics suggest strong investment potential with favorable risk/reward.
DexCom Inc (DXCM) Key Strengths (7)
Every $100 of shareholder equity generates $35 in profit
Earnings per share surging 78.00% year-over-year
100.98% of shares held by major funds and institutions
Large-cap company with substantial market presence
Good growth relative to its price
Strong operational efficiency: $26 kept per $100 revenue
Strong profitability: $18 kept per $100 revenue
Supporting Valuation Data
DexCom Inc (DXCM) Areas to Watch (3)
Very expensive at 9.3x book value
Premium valuation at 5.6x annual revenue
Solid revenue growth at 13.10% per year
Supporting Valuation Data
DexCom Inc (DXCM) Detailed Analysis Report
Overall Assessment
This company scores 72/100 in our Smart Analysis, earning a B grade. Out of 10 metrics analyzed, 7 register as strengths (avg 9.0/10) while 3 fall into concern territory (avg 4.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Return on Equity, EPS Growth, Institutional Own.. Valuation metrics including PEG Ratio (1.46) suggest the stock is attractively priced. Profitability is solid with Return on Equity at 34.50%, Operating Margin at 25.60%, Profit Margin at 17.90%. Growth metrics are encouraging with EPS Growth at 78.00%.
The Bear Case
The primary concerns are Price/Book, Price/Sales, Revenue Growth. Some valuation metrics including Price/Sales (5.59), Price/Book (9.33) suggest expensive pricing. Growth concerns include Revenue Growth at 13.10%, which may limit upside.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Price/Book improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 34.50% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at 13.10% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate risk investment. The weight of evidence leans positive, with more strengths than concerns. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
The combination of Return on Equity and EPS Growth makes a compelling case at current levels. The key risk is Price/Book, but the overall fundamental picture is positive with a clear path to maintaining or improving the current B grade.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
DXCM Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
DXCM's Price-to-Sales ratio of 5.59x trades at a deep discount to its historical average of 70.37x (0th percentile). The current valuation is 99% below its historical high of 464.43x set in Feb 2007, and 4% above its historical low of 5.37x in Mar 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for DexCom Inc (DXCM) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
DexCom Inc is a mature, profitable business with steady cash generation. Revenue reached 4.7B with 13% growth year-over-year. Profit margins of 17.9% are healthy, with room for further expansion as the business scales.
Key Findings
ROE of 3450.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Generating 192M in free cash flow and 294M in operating cash flow. Earnings are translating into actual cash generation.
What to Watch Next
Volatility is elevated with a beta of 1.53, so expect amplified moves relative to the broader market.
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact DexCom Inc.
Bottom Line
DexCom Inc is a well-established business delivering consistent profitability with 17.9% margins. The growth phase may be slowing, but strong cash generation and operational efficiency make it suitable for investors seeking reliability over excitement.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About DexCom Inc(DXCM)
NASDAQ
HEALTHCARE
MEDICAL DEVICES
USA
DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has a manufacturing facility in Mesa, Arizona.